Zealand Pharma`s dasiglucagon Phase 2a results at the 11th International Conference on ATTD
(WorldNews Denmark)

Press release - No. 3/2018 Zealand Pharma`s dasiglucagon Phase 2a results will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes Dasiglucagon was dosed using the automated dual-hormone artificial pancreas algorithm in development for the leading dual-hormone pump, iLetTM. Dasiglucagon, a novel glucagon analog suitable for pump use, was effective in controlling blood glucose when used together with insulin in patients with type 1 diabetes. Copenhagen, February 15, 2018 - Dr. Steven J. Russell, Massachusetts General Hospital, Boston, U.S., principal investigator for Zealand Pharma`s (`Zealand`) Phase 2a trial of dasiglucagon in patients with...